1428 related articles for article (PubMed ID: 30849247)
1. Broad-spectrum coronavirus antiviral drug discovery.
Totura AL; Bavari S
Expert Opin Drug Discov; 2019 Apr; 14(4):397-412. PubMed ID: 30849247
[TBL] [Abstract][Full Text] [Related]
2. Abelson Kinase Inhibitors Are Potent Inhibitors of Severe Acute Respiratory Syndrome Coronavirus and Middle East Respiratory Syndrome Coronavirus Fusion.
Coleman CM; Sisk JM; Mingo RM; Nelson EA; White JM; Frieman MB
J Virol; 2016 Oct; 90(19):8924-33. PubMed ID: 27466418
[TBL] [Abstract][Full Text] [Related]
3. Remdesivir against COVID-19 and Other Viral Diseases.
Malin JJ; Suárez I; Priesner V; Fätkenheuer G; Rybniker J
Clin Microbiol Rev; 2020 Dec; 34(1):. PubMed ID: 33055231
[TBL] [Abstract][Full Text] [Related]
4. SARS, MERS and SARS-CoV-2 (COVID-19) treatment: a patent review.
Nascimento Junior JAC; Santos AM; Quintans-Júnior LJ; Walker CIB; Borges LP; Serafini MR
Expert Opin Ther Pat; 2020 Aug; 30(8):567-579. PubMed ID: 32429703
[TBL] [Abstract][Full Text] [Related]
5. The broad-spectrum antiviral recommendations for drug discovery against COVID-19.
Hazafa A; Ur-Rahman K; Haq IU; Jahan N; Mumtaz M; Farman M; Naeem H; Abbas F; Naeem M; Sadiqa S; Bano S
Drug Metab Rev; 2020 Aug; 52(3):408-424. PubMed ID: 32546018
[TBL] [Abstract][Full Text] [Related]
6. In vitro virucidal activity of Echinaforce®, an Echinacea purpurea preparation, against coronaviruses, including common cold coronavirus 229E and SARS-CoV-2.
Signer J; Jonsdottir HR; Albrich WC; Strasser M; Züst R; Ryter S; Ackermann-Gäumann R; Lenz N; Siegrist D; Suter A; Schoop R; Engler OB
Virol J; 2020 Sep; 17(1):136. PubMed ID: 32907596
[TBL] [Abstract][Full Text] [Related]
7. Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses.
Artese A; Svicher V; Costa G; Salpini R; Di Maio VC; Alkhatib M; Ambrosio FA; Santoro MM; Assaraf YG; Alcaro S; Ceccherini-Silberstein F
Drug Resist Updat; 2020 Dec; 53():100721. PubMed ID: 33132205
[TBL] [Abstract][Full Text] [Related]
8. Compounds with Therapeutic Potential against Novel Respiratory 2019 Coronavirus.
Martinez MA
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152082
[TBL] [Abstract][Full Text] [Related]
9. Alisporivir inhibits MERS- and SARS-coronavirus replication in cell culture, but not SARS-coronavirus infection in a mouse model.
de Wilde AH; Falzarano D; Zevenhoven-Dobbe JC; Beugeling C; Fett C; Martellaro C; Posthuma CC; Feldmann H; Perlman S; Snijder EJ
Virus Res; 2017 Jan; 228():7-13. PubMed ID: 27840112
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of lopinavir therapy for SARS coronavirus and MERS coronavirus-A possible reference for coronavirus disease-19 treatment option.
Yao TT; Qian JD; Zhu WY; Wang Y; Wang GQ
J Med Virol; 2020 Jun; 92(6):556-563. PubMed ID: 32104907
[TBL] [Abstract][Full Text] [Related]
11. TMPRSS2 Contributes to Virus Spread and Immunopathology in the Airways of Murine Models after Coronavirus Infection.
Iwata-Yoshikawa N; Okamura T; Shimizu Y; Hasegawa H; Takeda M; Nagata N
J Virol; 2019 Mar; 93(6):. PubMed ID: 30626688
[TBL] [Abstract][Full Text] [Related]
12. Broad Cross-Species Infection of Cultured Cells by Bat HKU2-Related Swine Acute Diarrhea Syndrome Coronavirus and Identification of Its Replication in Murine Dendritic Cells
Yang YL; Qin P; Wang B; Liu Y; Xu GH; Peng L; Zhou J; Zhu SJ; Huang YW
J Virol; 2019 Dec; 93(24):. PubMed ID: 31554686
[TBL] [Abstract][Full Text] [Related]
13. What are our pharmacotherapeutic options for MERS-CoV?
Al-Tawfiq JA; Memish ZA
Expert Rev Clin Pharmacol; 2014 May; 7(3):235-8. PubMed ID: 24580083
[TBL] [Abstract][Full Text] [Related]
14. Middle East Respiratory Syndrome Virus Pathogenesis.
Singh SK
Semin Respir Crit Care Med; 2016 Aug; 37(4):572-7. PubMed ID: 27486737
[TBL] [Abstract][Full Text] [Related]
15. HTCC as a Polymeric Inhibitor of SARS-CoV-2 and MERS-CoV.
Milewska A; Chi Y; Szczepanski A; Barreto-Duran E; Dabrowska A; Botwina P; Obloza M; Liu K; Liu D; Guo X; Ge Y; Li J; Cui L; Ochman M; Urlik M; Rodziewicz-Motowidlo S; Zhu F; Szczubialka K; Nowakowska M; Pyrc K
J Virol; 2021 Jan; 95(4):. PubMed ID: 33219167
[TBL] [Abstract][Full Text] [Related]
16. Sensitivity of SARS/MERS CoV to interferons and other drugs based on achievable serum concentrations in humans.
Strayer DR; Dickey R; Carter WA
Infect Disord Drug Targets; 2014; 14(1):37-43. PubMed ID: 25019238
[TBL] [Abstract][Full Text] [Related]
17. [Diagnosis, treatment, control and prevention of SARS-CoV-2 and coronavirus disease 2019: back to the future].
Ye ZW; Jin DY
Sheng Wu Gong Cheng Xue Bao; 2020 Apr; 36(4):571-592. PubMed ID: 32347053
[TBL] [Abstract][Full Text] [Related]
18. 3C-like protease inhibitors block coronavirus replication in vitro and improve survival in MERS-CoV-infected mice.
Rathnayake AD; Zheng J; Kim Y; Perera KD; Mackin S; Meyerholz DK; Kashipathy MM; Battaile KP; Lovell S; Perlman S; Groutas WC; Chang KO
Sci Transl Med; 2020 Aug; 12(557):. PubMed ID: 32747425
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic options for Middle East respiratory syndrome coronavirus (MERS-CoV)--possible lessons from a systematic review of SARS-CoV therapy.
Momattin H; Mohammed K; Zumla A; Memish ZA; Al-Tawfiq JA
Int J Infect Dis; 2013 Oct; 17(10):e792-8. PubMed ID: 23993766
[TBL] [Abstract][Full Text] [Related]
20. Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture.
de Wilde AH; Jochmans D; Posthuma CC; Zevenhoven-Dobbe JC; van Nieuwkoop S; Bestebroer TM; van den Hoogen BG; Neyts J; Snijder EJ
Antimicrob Agents Chemother; 2014 Aug; 58(8):4875-84. PubMed ID: 24841269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
